依达拉奉治疗出血性脑梗死的疗效及其对IL-1β和IL-6的影响

Study on the Clinical Effects of Edaravone on Hemorrhagic Cerebral Infarction Patients and Influence of IL-1β and IL-6 level

目的观察依达拉奉对出血性脑梗死患者的疗效及其对IL-1β和IL-6水平影响。方法 120例出血性脑梗死患者随机分为观察组和对照组,每组60例。对照组患者给予甘露醇等常规药物治疗,观察组在此基础上加用依达拉奉治疗。比较两组患者短期疗效、神经功能、生活能力及炎症因子水平变化。结果治疗后观察组总有效率显著高于对照组患者(P<0.05)。治疗后,观察组患者ESS评分及ADL评分均显著高于对照组患者(P<0.05)。治疗后,观察组患者血清IL-1β和IL-6水平均显著低于对照组患者(P<0.01)。结论依达拉奉可有效减轻血性脑梗死患者炎症反应进而提高疗效、保护神经功能。

Objective To investigate the clinical effects of edaravone on hemorrhagic cerebral infarction（HCI） patients and influence of IL-1β and IL-6 level. Methods 120 cases of HCI patients were randomly divided into observation group and control group, each group of 60 cases. The control group were treated with mannitol and other conventional drug treatment,the observation group were treated by edaravone additionally. The short-term efficacy, neurological function, life ability and inflammatory factors were compared between the two groups. Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group（P 〈 0. 05）. After treatment,the ESS score and ADL score of the observation group were significantly higher than those of the control group （ P 〈 0. 05 ）. After treatment, the serum IL-1β and IL-6 in the observation group were significantly lower than those in the control group（ P 〈 0. 01 ）. Conclusion Edaravone can effectively reduce inflammation in patients with HCI and improve the overall response efficacy ,protect nerve function.